<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0e7d3da8-78fa-b4ae-4a43-15919e900ebe"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information
needed to use MULTIHANCE safely and effectively. See full prescribing
information for MULTIHANCE.<br/>MultiHance (gadobenate dimeglumine)
Injection<br/>Initial U.S. Approval: 2004</title>
   <effectiveTime value="20250314"/>
   <setId root="59077a3e-5f03-4342-ae24-856267545631"/>
   <versionNumber value="20"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
            <name>BRACCO DIAGNOSTICS INC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="849234661" root="1.3.6.1.4.1.519.1"/>
                  <name>BRACCO DIAGNOSTICS INC</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="434384007" root="1.3.6.1.4.1.519.1"/>
                        <name>BRACCO IMAGING SPA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="342104149" root="1.3.6.1.4.1.519.1"/>
                        <name>BIPSO GmbH</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="314929072" root="1.3.6.1.4.1.519.1"/>
                        <name>Labor LS SE &amp; Co. KG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="434078638" root="1.3.6.1.4.1.519.1"/>
                        <name>PATHEON ITALIA SPA</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="318354230" root="1.3.6.1.4.1.519.1"/>
                        <name>BioChem Labor  für biologishe und chemische</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="49d6062f-2250-4dd7-b9e6-9d3bceb07b18"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20180110"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0270-5164" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>MultiHance</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>gadobenate dimeglumine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="529" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3Q6PPC19PO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>gadobenate dimeglumine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="AZV954TZ9N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GADOLINIUM CATION (3+)</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-5164-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20041123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-5164-13" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20041123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-5164-14" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20041123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0270-5164-15" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20041123"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021357" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20041123"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="4cee15ed-ad39-da8f-184b-2a51b5cc14e7"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC
FIBROSIS</title>
               <text>
                  <paragraph ID="p29759701706059094">
                     <content styleCode="bold">
                        <content styleCode="underline">Risk Associated with Intrathecal Use</content>
                     </content>
                     <br/>
                     <content styleCode="bold">Intrathecal administration of gadolinium-based
contrast agents (GBCAs) can cause serious adverse reactions including
death, coma, encephalopathy, and seizures. MultiHance is not approved
for intrathecal use <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.1">(5.1)</linkHtml>]</content>.</content>
                  </paragraph>
                  <paragraph ID="p26339701706059186">
                     <content styleCode="bold">
                        <content styleCode="underline">Nephrogenic Systemic Fibrosis</content>
                     </content>
                     <br/>
                     <content styleCode="bold">GBCAs increase the risk for nephrogenic
systemic fibrosis (NSF) among patients with impaired elimination of
the drugs. Avoid use of MultiHance in these patients unless the diagnostic
information is essential and not available with non-contrasted MRI
or other modalities. NSF may result in fatal or debilitating systemic
fibrosis affecting the skin, muscle and internal organs.</content>
                  </paragraph>
                  <paragraph ID="p1436729701706059257">
                     <content styleCode="bold">The risk for NSF appears
highest among patients with:</content>
                  </paragraph>
                  <list listType="unordered" ID="l1435739701706059277" styleCode="Circle">
                     <item>
                        <content styleCode="bold">chronic, severe kidney disease (GFR &lt;30 mL/min/1.73m<sup>2</sup>), or</content>
                     </item>
                     <item>
                        <content styleCode="bold">acute kidney injury.</content>
                     </item>
                  </list>
                  <paragraph ID="p1895159701706059328">
                     <content styleCode="bold">Screen patients
for acute kidney injury and other conditions that may reduce renal
function. For patients at risk for chronically reduced renal function
(e.g. age &gt; 60 years, hypertension or diabetes), estimate the glomerular
filtration rate (GFR) through laboratory testing.</content>
                  </paragraph>
                  <paragraph ID="p1895639701706059333">
                     <content styleCode="bold">For patients at highest
risk for NSF, do not exceed the recommended MultiHance dose and allow
a sufficient period of time for elimination of the drug from the body
prior to re-administration <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.2">(5.2)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p304122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">WARNING: RISK ASSOCIATED WITH
INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p517122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">See full prescribing
information for complete boxed warning</content>
                              </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="l55937101705977106" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Intrathecal administration of gadolinium based contrast
agents (GBCAs) can cause serious adverse reactions including death,
coma, encephalopathy, and seizures. MultiHance is not approved for
intrathecal use. <linkHtml href="#Section_5.1">(5.1)</linkHtml>
                              </content>
                           </item>
                           <item>
                              <content styleCode="bold">GBCAs increase the risk for nephrogenic systemic fibrosis
(NSF) among patients with impaired elimination of the drugs. Avoid
use of MultiHance in these patients unless the diagnostic information
is essential and not available with non-contrast MRI or other modalities.
The risk for NSF appears highest among patients with:</content>
                              <list listType="unordered" ID="l1412937101705977228" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">chronic, severe kidney disease (GFR &lt;30 mL/min/1.73m<sup>2</sup>), or</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">acute kidney injury.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">Screen patients for acute kidney injury and other conditions
that may reduce renal function. For patients at risk for chronically
reduced renal function (e.g. age &gt;60 years, hypertension or diabetes),
estimate the glomerular filtration rate (GFR) through laboratory testing. <linkHtml href="#Section_5.2">(5.2)</linkHtml>
                              </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="3857af50-b447-70ab-1649-44f2e31329d0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1  INDICATIONS AND USAGE</title>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l788122" styleCode="Disc">
                           <item>magnetic resonance imaging (MRI) of the central nervous
system (CNS) in adults and pediatric patients (including term neonates),
to visualize lesions with abnormal blood-brain barrier or abnormal
vascularity of the brain, spine, and associated tissues. <linkHtml href="#Section_1.1">(1.1)</linkHtml>
                           </item>
                           <item>magnetic resonance angiography (MRA) to evaluate adults
with known or suspected renal or aorto-ilio-femoral occlusive vascular
disease. <linkHtml href="#Section_1.2">(1.2)</linkHtml>
                           </item>
                        </list>
                        <paragraph ID="p189612301741951011">
                           <br/>
                           <br/>
                           <br/>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="2e2978e4-aef4-6027-89ae-8e54fd0c7d77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1  Magnetic Resonance
Imaging (MRI) of the Central Nervous System (CNS)</title>
                     <text>
                        <paragraph ID="p808122">MultiHance is indicated for intravenous use
in magnetic resonance imaging (MRI) of the central nervous system
(CNS) in adults and pediatric patients (including term neonates),
to visualize lesions with abnormal blood-brain barrier or abnormal
vascularity of the brain, spine, and associated tissues.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="a9a152c7-6681-cc66-6b70-aa0c532bfef9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2  Magnetic Resonance
Angiography (MRA) of Renal and Aorto-ilio-femoral Vessels</title>
                     <text>
                        <paragraph ID="p816122">MultiHance is indicated for use in magnetic
resonance angiography (MRA) to evaluate adults with known or suspected
renal or aorto-ilio-femoral occlusive vascular disease.</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="43bbf32b-18c8-4bfa-9266-468580aa2cbb"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2  DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20180402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l1411964521516996294" styleCode="Disc">
                           <item>The recommended dose of MultiHance is 0.2 mL/kg (0.1 mmol/kg)
administered as a rapid bolus intravenous injection.</item>
                           <item>For MRI of the CNS in pediatric patients below 2 years of
age the recommended dosage range is 0.1 to 0.2 mL/kg.</item>
                           <item>To ensure complete injection of the contrast medium, follow
the injection with a saline flush of at least 5 mL in MRI of the CNS
and at least 20 mL in MRA. (<linkHtml href="#Section_2">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="9904d9fd-a0ed-da45-ed25-aa1f8f2acf50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Dosing and Imaging Instructions</title>
                     <effectiveTime value="20180117"/>
                     <component>
                        <section ID="Section_2.1.1">
                           <id root="8ac58e7e-1f0f-fda2-e64a-e39938780c49"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>2.1.1 MRI of the CNS</title>
                           <text>
                              <paragraph ID="p1050122">In adults and in pediatric patients over
2 years of age, the recommended dose of MultiHance for MRI of the
CNS is 0.2 mL/kg (0.1 mmol/kg) administered as a rapid bolus intravenous
injection. In pediatric patients below 2 years of age, the recommended
dosage range is 0.1 to 0.2 mL/kg administered as a rapid bolus intravenous
injection.  To ensure complete injection of the contrast medium, follow
the injection with a saline flush of at least 5 mL. Imaging of the
CNS can be performed starting immediately after the bolus injection
of MultiHance.</paragraph>
                           </text>
                           <effectiveTime value="20180117"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_2.1.2">
                           <id root="47740dfd-b8f9-824b-911f-46455dd9db1a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>2.1.2 MRA of Renal and
Aorto-ilio-femoral Vessels</title>
                           <text>
                              <paragraph ID="p1067122">For MRA examination, the recommended dose is 0.2 mL/kg (0.1 mmol/kg)
administered as a rapid bolus intravenous injection followed by at
least 20 mL saline flush either manually or using an automatic injector
system. Start imaging immediately after the administration of MultiHance,
with scan delay calculated by test bolus or automatic bolus detection
technique. If an automatic contrast detection pulse sequence is not
used for bolus timing, then a test bolus injection of 1-2 mL of MultiHance
should be used to calculate the appropriate scan delay.</paragraph>
                           </text>
                           <effectiveTime value="20180117"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="92d65781-3398-41ab-8f6a-35c2acd2a563"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Dosing Table</title>
                     <text>
                        <table ID="Table1" border="0" width="100%">
                           <colgroup>
                              <col width="24*"/>
                              <col width="25*"/>
                              <col width="24*"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">*For pediatric patients
less than 2 years of age, one-half of the per kg dose may be used.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3" align="center">
                                    <content styleCode="bold">TABLE 1: WEIGHT-BASED DOSING VOLUMES FOR:<br/>CNS IMAGING
(ADULTS AND PEDIATRICS ≥2 YEARS OF AGE*)<br/>AND<br/>MRA IMAGING (ADULTS ONLY) </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center"> </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center"> </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">0.1mM/kg dose</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">Kilograms (Kg)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">Pounds (lb)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">Volume, Milliliters
(mL)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">2.5</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">5.5</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">0.5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">5</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">11</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">1.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">10</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">22</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">2.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">15</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">33</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">3.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">20</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">44</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">4.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">25</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">55</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">5.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">30</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">66</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">6.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">35</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">77</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">7.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">40</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">88</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">8.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">45</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">99</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">9.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">50</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">110</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">10.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">55</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">121</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">11.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">60</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">132</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">12.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">65</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">143</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">13.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">70</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">154</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">14.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">75</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">165</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">15.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">80</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">176</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">16.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">85</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">187</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">17.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">90</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">198</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">18.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">95</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">209</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">19.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">100</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">220</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">20.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">105</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">231</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">21.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">110</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">242</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">22.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">115</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">253</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">23.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">120</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">264</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">24.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">125</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">275</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">25.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">130</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">286</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">26.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">135</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">297</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">27.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">140</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">308</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">28.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">145</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">319</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">29.0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">150</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">330</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">30.0</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20180402"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="82ff3ab5-bf9e-71a5-08be-0921b501b782"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Administration</title>
                     <text>
                        <paragraph ID="p159211122">Inspect the MultiHance vial visually for
particulate matter and discoloration prior to administration. Do not
use the solution if it is discolored or particulate matter is present.
 Draw MultiHance into a syringe and inject using sterile technique.</paragraph>
                        <paragraph ID="p159161222">Do not mix intravenous medications or
parenteral nutrition solutions with MultiHance. Do not administer
other medications in the same intravenous line with MultiHance.</paragraph>
                        <paragraph ID="p158751022">MultiHance vials are intended for single
use only. Administer immediately after opening and discard any unused
product.</paragraph>
                     </text>
                     <effectiveTime value="20130122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="3919da8a-516b-3aff-d5e0-bc30be6fb838"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="p3348122">MultiHance is a sterile, nonpyrogenic, clear,
colorless to slightly yellow aqueous solution for intravenous use
only, containing 529 mg gadobenate dimeglumine per mL.</paragraph>
               </text>
               <effectiveTime value="20130122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p3352122">Each mL of MultiHance Injection contains
529 mg gadobenate dimeglumine and is available in single use vials. <linkHtml href="#Section_3">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="07696bc6-100b-845f-e030-cad9a88481b9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4  CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="p3364122">MultiHance is contraindicated in patients with known allergic or
hypersensitivity reactions to gadolinium-based contrast agents [<content styleCode="italics">
                        <content styleCode="emphasis">see Warnings and Precautions <linkHtml href="#Section_5.3">(5.3)</linkHtml>
                        </content>
                     </content>].</paragraph>
               </text>
               <effectiveTime value="20240123"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p3377122">MultiHance is contraindicated in patients
with known allergic or hypersensitivity reactions to gadolinium-based
contrast agents. <linkHtml href="#Section_4">(4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="5b13aeb7-3134-826c-f141-7ac9824ea2aa"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5  WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l3596122" styleCode="Disc">
                           <item>Hypersensitivity: anaphylactic/anaphylactoid reactions with
cardiovascular, respiratory and cutaneous manifestations, ranging
from mild to severe reactions including shock can occur. Monitor patients
closely for need of emergency cardiorespiratory support. <linkHtml href="#Section_5.3">(5.3)</linkHtml>
                           </item>
                           <item>Gadolinium is retained for months or years in brain, bone,
and other organs. <linkHtml href="#Section_5.3">(5.4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="6a5ac126-b7aa-87ff-72f6-ba6154a2e6a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Risk Associated
with Intrathecal Use</title>
                     <text>
                        <paragraph ID="p15390127101705977783">Intrathecal administration of GBCAs can
cause serious adverse reactions including death, coma, encephalopathy,
and seizures. The safety and effectiveness of MultiHance have not
been established with intrathecal use. MultiHance is not approved
for intrathecal use <content styleCode="italics">[see Dosage and Administration <linkHtml href="#Section_2.1">(2.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="a18c6cc5-8228-82d8-62f9-b070ba8ab492"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Nephrogenic Systemic
Fibrosis</title>
                     <text>
                        <paragraph ID="p3616122">GBCAs increase
the risk for nephrogenic systemic fibrosis (NSF) among patients with
impaired elimination of the drugs. Avoid use of MultiHance among these
patients unless the diagnostic information is essential and not available
with non-contrast enhanced MRI or other modalities. The GBCA-associated
NSF risk appears highest for patients with chronic, severe kidney
disease (GFR &lt;30 mL/min/1.73m<sup>2</sup>) as well
as patients with acute kidney injury. The risk appears lower for patients
with chronic, moderate kidney disease (GFR 30-59 mL/min/1.73m<sup>2</sup>) and little, if any, for patients with chronic, mild
kidney disease (GFR 60-89 mL/min/1.73m<sup>2</sup>). NSF may result in fatal or debilitating fibrosis affecting the
skin, muscle and internal organs. Report any diagnosis of NSF following
MultiHance administration to Bracco Diagnostics (1-800-257-5181) or
FDA (1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>).</paragraph>
                        <paragraph ID="p3843122">Screen patients for acute
kidney injury and other conditions that may reduce renal function.
Features of acute kidney injury consist of rapid (over hours to days)
and usually reversible decrease in kidney function, commonly in the
setting of surgery, severe infection, injury or drug-induced kidney
toxicity. Serum creatinine levels and estimated GFR may not reliably
assess renal function in the setting of acute kidney injury. For patients
at risk for chronically reduced renal function (e.g., age &gt;60 years,
diabetes mellitus or chronic hypertension), estimate the GFR through
laboratory testing.</paragraph>
                        <paragraph ID="p3846122">Among the
factors that may increase the risk for NSF are repeated or higher
than recommended doses of a GBCA and the degree of renal impairment
at the time of exposure. Record the specific GBCA and the dose administered
to a patient. For patients at highest risk for NSF, do not exceed
the recommended MultiHance dose and allow a sufficient period of time
for elimination of the drug prior to re-administration. For patients
receiving hemodialysis, physicians may consider the prompt initiation
of hemodialysis following the administration of a GBCA in order to
enhance the contrast agent’s elimination. The usefulness of hemodialysis
in the prevention of NSF is unknown [<content styleCode="italics">see Dosage and Administration <linkHtml href="#Section_2">(2)</linkHtml> and Clinical Pharmacology <linkHtml href="#Section_12">(12)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20240826"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="358fc0c2-28e2-7b0a-3eb6-0b6b993ceb53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Hypersensitivity Reactions</title>
                     <text>
                        <paragraph ID="p3868122">Anaphylactic and anaphylactoid reactions have been reported,
involving cardiovascular, respiratory, and/or cutaneous manifestations.
 Some patients experienced circulatory collapse and died. In most
cases, initial symptoms occurred within minutes of MultiHance administration
and resolved with prompt emergency treatment.</paragraph>
                        <paragraph ID="p3871122">Prior to MultiHance administration, ensure the availability
of personnel trained and medications to treat hypersensitivity reactions.
 If such a reaction occurs stop MultiHance and immediately begin appropriate
therapy. Additionally, consider the risk for hypersensitivity reactions,
especially in patients with a history of hypersensitivity reactions
or a history of asthma or other allergic disorders.  Observe patients
for signs and symptoms of a hypersensitivity reaction during and for
up to 2 hours after MultiHance administration.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="4bb61373-9c4e-f160-b28f-7d5db3f61c10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Gadolinium Retention</title>
                     <text>
                        <paragraph ID="Paragraph-1193-4A32CC53">Gadolinium is retained for months or
years in several organs. The highest concentrations (nanomoles per
gram of tissue) have been identified in the bone, followed by other
organs (e.g. brain, skin, kidney, liver, and spleen). The duration
of retention also varies by tissue and is longest in bone. Linear
GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses,
gadolinium retention varies among the linear agents with Omniscan
(gadodiamide) and Optimark (gadoversetamide) causing greater retention
than other linear agents [Eovist (gadoxetate disodium), Magnevist
(gadopentetate dimeglumine), MultiHance (gadobenate dimeglumine)].
Retention is lowest and similar among the macrocyclic GBCAs [Dotarem
(gadoterate meglumine), Gadavist (gadobutrol), ProHance (gadoteridol)].</paragraph>
                        <paragraph ID="p161301529011515687026">Consequences of gadolinium
retention in the brain have not been established. Pathologic and clinical
consequences of GBCA administration and retention in skin and other
organs have been established in patients with impaired renal function <content styleCode="italics"> [see Warnings and Precautions <linkHtml href="#Section_5.2">(5.2)</linkHtml>]</content>. There are rare reports of pathologic skin changes in
patients with normal renal function. Adverse events involving multiple
organ systems have been reported in patients with normal renal function
without an established causal link to gadolinium retention <content styleCode="italics"> [see Adverse Reactions <linkHtml href="#Section_6.2">(6.2)</linkHtml>]</content>.</paragraph>
                        <paragraph ID="p161621229011515687228">While clinical
consequences of gadolinium retention have not been established in
patients with normal renal function, certain patients might be at
higher risk. These include patients requiring multiple lifetime doses,
pregnant and pediatric patients, and patients with inflammatory conditions.
Consider the retention characteristics of the agent when choosing
a GBCA for these patients. Minimize repetitive GBCA imaging studies,
particularly closely spaced studies when possible.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="1bb3e866-a8b5-8802-19ae-c2f6d35ee11f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5  Acute Renal Failure</title>
                     <text>
                        <paragraph ID="p3879122">In patients with renal insufficiency, acute renal failure requiring
dialysis or worsening renal function have occurred with the use of
gadolinium-based contrast agents.  The risk of renal failure may increase
with increasing dose of the contrast agent.  Screen all patients for
renal dysfunction by obtaining a history and/or laboratory tests.
 Consider follow-up renal function assessments for patients with a
history of renal dysfunction.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="2e1232aa-66ef-9dd9-647c-10aadf394198"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6  Extravasation and Injection Site Reactions</title>
                     <text>
                        <paragraph ID="p3887122">Extravasation of MultiHance may lead to
injection site reactions, characterized by local pain or burning sensation,
swelling, blistering, and necrosis.  In animal experiments, local
reactions including eschar and necrosis were noted even on Day 8 post
perivenous injection of MultiHance.  Exercise caution to avoid local
extravasation during intravenous administration of MultiHance. If
extravasation occurs, evaluate and treat as necessary if local reactions
develop.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="66b73bdf-d049-e581-e7e3-82ca9442b9af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7  Cardiac Arrhythmias</title>
                     <text>
                        <paragraph ID="p4101122">Cardiac arrhythmias have been observed in patients receiving MultiHance
in clinical trials [<content styleCode="italics">see Adverse Reactions <linkHtml href="#Section_6.1">(6.1)</linkHtml>
                           </content>]. Assess patients for underlying
conditions or medications that predispose to arrhythmias.</paragraph>
                        <paragraph ID="p4113122">A double-blind, placebo-controlled, 24-hour
post dose continuous monitoring, crossover study in 47 subjects evaluated
the effect of 0.2 mmol/kg MultiHance on ECG intervals, including QTc.
 The average changes in QTc values compared with placebo were minimal
(&lt;5 msec).  QTc prolongation between 30 and 60 msec were noted
in 20 subjects who received MultiHance vs. 11 subjects who received
placebo.  Prolongations ≥61 msec were noted in 6 subjects who received
MultiHance and in 3 subjects who received placebo.  None of these
subjects had associated malignant arrhythmias.  The effects on QTc
by MultiHance dose, other drugs, and medical conditions were not systematically
studied.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="e4069adb-4c7b-8666-bcf2-f21fb21a78fa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8  Interference with Visualization of Certain Lesions</title>
                     <text>
                        <paragraph ID="p4121122">Certain lesions seen on non-contrast images
may not be seen on contrast- images. Exercise caution when interpreting
contrast MR images in the absence of companion non-contrast MR images.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="21f2dce7-19b5-621f-0665-2772058d2962"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6  ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="p18948422">The following adverse reactions are discussed in greater detail in
other sections of the label:</paragraph>
                  <list listType="unordered" ID="l18975422" styleCode="Disc">
                     <item>Nephrogenic systemic fibrosis <content styleCode="italics">[see Warnings and
Precautions <linkHtml href="#Section_5.2">(5.2)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.3">(5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250314"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p4130122">The most commonly reported adverse reactions
are nausea (1.3%) and headache (1.2%). <linkHtml href="#Section_6">(6)</linkHtml>
                        </paragraph>
                        <paragraph ID="p4139122">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS,
contact Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088
or <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="05509d82-98c1-f5d0-1c9d-b6b895b65fb6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1  Clinical Trials
Experience</title>
                     <text>
                        <paragraph ID="p4358122">Because clinical
trials are conducted under widely varying conditions, adverse reaction
rates observed in the clinical trials of a drug cannot be directly
compared to rates in the clinical trials of another drug and may not
reflect the rates observed in practice.</paragraph>
                        <paragraph ID="p4361122">
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph ID="p4368122">In clinical trials with MultiHance, a total of 4967
adult subjects (137 healthy volunteers and 4830 patients) received
MultiHance at doses ranging from 0.005 to 0.4 mmol/kg.  There were
2838 (57%) men and 2129 (43%) women with a mean age of 56.5 years
(range 18 to 93 years).  A total of 4403 (89%) subjects were Caucasian,
134 (3%) Black, 275 (6%) Asian, 40 (1%) Hispanic, 70 (1%) in other
racial groups, and for 45 (1%) subjects, race was not reported.</paragraph>
                        <paragraph ID="p4373122">The most commonly reported adverse reactions
in adult subjects who received MultiHance were nausea (1.3%) and headache
(1.2%). Most adverse reactions were mild to moderate in intensity.
One subject experienced a serious anaphylactoid reaction with laryngeal
spasm and dyspnea [<content styleCode="italics">see Warnings and Precautions <linkHtml href="#Section_5.3">(5.3)</linkHtml>
                           </content>]. Serious adverse reactions
consisting of convulsions, pulmonary edema, acute necrotizing pancreatitis,
and anaphylactoid reactions were reported in 0.1% of subjects in clinical
trials.</paragraph>
                        <paragraph ID="p4392122">Adverse reactions that
occurred in at least 0.5% of 4967 adult subjects who received MultiHance
are listed below (Table 2), in decreasing order of occurrence within
each system.</paragraph>
                        <table ID="t1584622" border="0" cellpadding="1" cellspacing="1" width="100%">
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="2" align="center">
                                    <content styleCode="bold">TABLE 2: ADVERSE REACTIONS REPORTED IN ≥ 0.5% OF ADULT SUBJECTS
WHO RECEIVED MULTIHANCE IN CLINICAL TRIALS</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="left">Number of subjects
dosed</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">4967</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="left">Number of subjects
with any adverse reaction</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">517 (10.4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="left">Gastrointestinal
Disorders<br/>Nausea</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">  67 (1.3%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="left">General Disorders
and Administration Site Disorders<br/>Injection Site Reaction<br/>Feeling Hot</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">  54 (1.1%)<br/>49 (1.0%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="left">Nervous System
Disorders<br/>Headache<br/>Dysgeusia<br/>Paresthesia<br/>Dizziness</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">  60 (1.2%)<br/>33 (0.7%)<br/>24 (0.5%)<br/>24 (0.5%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p4912122">The following adverse reactions occurred
in less than 0.5% of the 4967 adult subjects who received MultiHance.
Serious adverse reactions described above are not repeated below.<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Blood and Lymphatic System Disorders: </content>
                           </content> Basophilia;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Cardiac Disorders: </content>
                           </content> Atrioventricular block first degree;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Eye Disorders: </content>
                           </content> Eye pruritus, eye swelling, ocular
hyperemia, visual disturbance;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Gastrointestinal
Disorders: </content>
                           </content> Abdominal pain or discomfort, diarrhea,
dry mouth, lip swelling, paresthesia oral, tongue edema, vomiting;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">General Disorders and Administration Site Conditions: </content>
                           </content> Chest pain or discomfort, chills, malaise;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Immune System Disorders: </content>
                           </content> Hypersensitivity;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Investigations: </content>
                           </content> Nonspecific changes
in laboratory tests (including hematology, blood chemistry, liver
enzymes and urinalysis), blood pressure and electrocardiogram parameters
(including PR, QRS and QT intervals and ST-T segment changes).<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Musculoskeletal and Connective Tissue Disorders: </content>
                           </content> Myalgia;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Nervous System Disorders: </content>
                           </content> Parosmia, tremor;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Respiratory,
Thoracic and Mediastinal Disorders: </content>
                           </content> Dyspnea, laryngospasm,
nasal congestion, sneezing, wheezing;<br/>
                           <content styleCode="bold">
                              <content styleCode="emphasis">Skin
and Subcutaneous Tissue Disorders: </content>
                           </content> Hyperhidrosis,
pruritus, rash, swelling face, urticaria.</paragraph>
                        <paragraph ID="p5638122">
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <paragraph ID="p5645122">In clinical trials of MultiHance in MRI
of the CNS, 307 pediatric subjects received MultiHance at a dose of
0.1 mmol/kg.  A total of 160 (52%) subjects were male and the overall
mean age was 6.0 years (range, 2 days to 17 years).  A total of 211
(69%) subjects were Caucasian, 24 (8%) Black, 15 (5%) Asian, 39 (13%),
Hispanic, 2 (&lt;1%) in other racial groups, and for 16 (5%), race
was not reported.</paragraph>
                        <paragraph ID="p5648122">Adverse reactions
were reported for 14 (4.6%) of the subjects.  The frequency and the
nature of the adverse reactions were similar to those seen in the
adult patients.  The most commonly reported adverse reactions were
vomiting (1.0%), pyrexia (0.7%), and hyperhidrosis (0.7%).  No subject
died during study participation.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="4416dace-bac4-6fc0-82e5-b5bf0063d060"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2  Postmarketing Experience</title>
                     <text>
                        <paragraph ID="p5656122">The following adverse reactions have been
identified during post approval use of MultiHance or other GBCAs.
 Because these reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate
their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph ID="p192002301722520717">
                           <content styleCode="bold">Gastrointestinal Disorders: </content>Acute pancreatitis with onset within 48 hours after GBCA administration.</paragraph>
                        <paragraph ID="p5659122">
                           <content styleCode="bold">Immune System Disorders:</content> Anaphylactic,
anaphylactoid and hypersensitivity reactions manifested with various
degrees of severity up to anaphylactic shock, loss of consciousness
and death.  The reactions generally involved signs or symptoms of
respiratory, cardiovascular, and/or mucocutaneous abnormalities.</paragraph>
                        <paragraph ID="p13851429011515687621">
                           <content styleCode="bold">General Disorders and
Administration Site Conditions:</content> Extravasation of MultiHance
may lead to injection site reactions, characterized by local pain
or burning sensation, swelling, blistering, and necrosis <content styleCode="italics">[see
Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p6438412991517240686">Adverse events
with variable onset and duration have been reported after GBCA administration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>. These include fatigue, asthenia, pain syndromes, and
heterogeneous clusters of symptoms in the neurological, cutaneous,
and musculoskeletal systems.</paragraph>
                        <paragraph ID="p189766301741848009">
                           <content styleCode="bold">Respiratory, Thoracic and Mediastinal
Disorders: </content>Acute respiratory distress syndrome, pulmonary edema</paragraph>
                        <paragraph ID="p16175029011515687867">
                           <content styleCode="bold">Skin:</content> Gadolinium
associated plaques.</paragraph>
                     </text>
                     <effectiveTime value="20250314"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="98e8ef11-7b0b-8bd8-38f2-8c7b027e21de"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7  DRUG INTERACTIONS</title>
               <effectiveTime value="20180403"/>
               <component>
                  <section ID="Section_7.1">
                     <id root="b26546ac-d39f-e8dd-d430-2531d1a6aeca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Transporter-Based
Drug-Drug Interactions</title>
                     <text>
                        <paragraph ID="p5681122">MultiHance and other drugs may compete for the canalicular multispecific
organic anion transporter (MOAT also referred to as MRP2 or ABCC2).
 Therefore MultiHance may prolong the systemic exposure of drugs such
as cisplatin, anthracyclines (e.g. doxorubicin, daunorubicin), vinca
alkaloids (e.g. vincristine), methotrexate, etoposide, tamoxifen,
and paclitaxel.  In particular, consider the potential for prolonged
drug exposure in patients with decreased MOAT activity (e.g. Dubin
Johnson syndrome).</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="93df3fad-f8e7-d940-cd7e-dca26f76383c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8  USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20180801"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p1894452341533668582">Pregnancy: Use only if imaging
is essential during pregnancy and cannot be delayed. (<linkHtml href="#Section_8.1">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="eeadb551-7153-aeec-1d94-e4e32cf9ee66"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1  Pregnancy</title>
                     <text>
                        <paragraph ID="p666655141516999103">
                           <content styleCode="underline">Risk Summary</content>
                           <br/>GBCAs cross the placenta
and result in fetal exposure and gadolinium retention. The human data
on the association between GBCAs and adverse fetal outcomes are limited
and inconclusive (<content styleCode="italics">see <linkHtml href="#Section_8.1_Data">Data</linkHtml>
                           </content>). In animal reproduction studies, gadobenate dimeglumine
has been shown to be teratogenic in rabbits following repeated intravenous
administration during organogenesis at doses up to 6 times the recommended
human dose. There were no adverse developmental effects observed in
rats with intravenous administration of gadobenate dimeglumine during
organogenesis at doses up to three times the recommended human dose <content styleCode="italics">(see <linkHtml href="#Section_8.1_Data">Data</linkHtml>).</content> Because
of the potential risks of gadolinium to the fetus, use MultiHance
only if imaging is essential and cannot be delayed.</paragraph>
                        <paragraph ID="p5907122">The estimated background risk of major birth defects
and miscarriage for the indicated population is unknown. All pregnancies
have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major
birth defects and miscarriage in clinically recognized pregnancies
is 2 to 4% and is 15 to 20%, respectively.</paragraph>
                        <paragraph ID="Section_8.1_Data">
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>Contrast enhancement is visualized
in the placenta and fetal tissues after maternal GBCA administration.</paragraph>
                        <paragraph ID="p1667655141516999298">Cohort studies and case reports
on exposure to GBCAs during pregnancy have not reported a clear association
between GBCAs and adverse effects in the exposed neonates. However,
a retrospective cohort study, comparing pregnant women who had a GBCA
MRI to pregnant women who did not have an MRI, reported a higher occurrence
of stillbirths and neonatal deaths in the group receiving GBCA MRI.
  Limitations of this study include a lack of comparison with non-contrast
MRI and lack of information about the maternal indication for MRI.
 Overall, these data preclude a reliable evaluation of the potential
risk of adverse fetal outcomes with the use of GBCAs in pregnancy.</paragraph>
                        <paragraph ID="p1665865141516999413">
                           <content styleCode="italics">Animal Data</content>
                           <br/>Gadolinium Retention<br/>GBCAs administered to
pregnant non-human primates (0.1 mmol/kg on gestational days 85 and
135) result in measurable gadolinium concentration in the offspring
in bone, brain, skin, liver, kidney, and spleen for at least 7 months.
GBCAs administered to pregnant mice (2 mmol/kg daily on gestational
days 16 through 19) result in measurable gadolinium concentrations
in the pups in bone, brain, kidney, liver, blood, muscle, and spleen
at one month postnatal age.<br/>Reproductive Toxicology<br/>Gadobenate dimeglumine has been shown to be teratogenic in rabbits
when administered intravenously at 2 mmol/kg/day (6 times the recommended
human dose based on body surface area) during organogenesis (day 6
to 18) inducing microphthalmia/small eye and/or focal retinal fold
in 3 fetuses from 3 separate litters. In addition, MultiHance administered
intravenously at 3 mmol/kg/day (10 times the recommended human dose
based on body surface area) has been shown to increase intrauterine
deaths in rabbits. There was no evidence that MultiHance induced teratogenic
effects in rats at doses up to 2 mmol/kg/day (3 times the recommended
human dose based on body surface area), however, rat dams exhibited
no systemic toxicity at this dose. There were no adverse effects on
the birth, survival, growth, development and fertility of the F1 generation
at doses up to 2 mmol/kg in a rat peri- and post-natal (Segment III)
study.</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="9fae9a71-d1ba-bd61-53eb-dcb3b4ae0190"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.2  Lactation</title>
                     <text>
                        <paragraph ID="p5915122">
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Limited literature reports that
breastfeeding after gadobenate dimeglumine administration to the mother
would result in the infant receiving an oral dose of 0.001%-0.04%
of the maternal dose. There is no information on the effects of the
drug on the breastfed infant or the effects of the drug on milk production.
Additionally, there is limited GBCA gastrointestinal absorption. The
developmental and health benefits of breastfeeding should be considered
together with the mother’s clinical need for MultiHance and any potential
adverse effects on the breastfed infant from MultiHance or from the
underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20180117"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="63dc00c3-39ab-a82d-8d08-0f1bdc4a2b24"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4  Pediatric Use</title>
                     <text>
                        <paragraph ID="p5923122">MultiHance
is approved for intravenous use for MRI of the CNS to visualize lesions
with abnormal blood brain barrier or abnormal vascularity of the brain,
spine, and associated tissues in pediatric patients from birth, including
term neonates, to less than 17 years of age.  Pediatric use is based
on evidence of effectiveness in adults and in 202 pediatric patients
2 years of age and older, in addition to experience in 105 pediatric
patients birth to less than 2 years of age that supported extrapolation
from adult data <content styleCode="italics">[see Clinical Studies (<linkHtml href="#Section_14">14</linkHtml>)]</content>. Adverse reactions in pediatric patients were
similar to those reported in adults <content styleCode="italics">[see Adverse Reactions
(<linkHtml href="#Section_6.1">6.1</linkHtml>)]</content>. No dose adjustment
according to age is necessary in pediatric patients two years of age
and older. For pediatric patients, less than 2 years of age, the recommended
dosage range is 0.1 to 0.2 mL/kg <content styleCode="italics">[see Dosage and Administration
(<linkHtml href="#Section_2.1">2.1</linkHtml>), Pharmacokinetics (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>. The safety of MultiHance
has not been established in preterm neonates.</paragraph>
                     </text>
                     <effectiveTime value="20180402"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="9a48a2bb-2c47-7ea0-1a4f-dddafe915b29"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5  Geriatric Use</title>
                     <text>
                        <paragraph ID="p5931122">Of
the total number of 4967 adult subjects in clinical studies of MultiHance,
33% were 65 or older.  No overall differences in safety or effectiveness
were observed between these elderly subjects and the younger subjects.</paragraph>
                        <paragraph ID="p5934122">The drug is known to be substantially excreted
by the kidney, and the risk of toxic reactions to MultiHance may be
greater in patients with impaired renal function.  Because elderly
patients are more likely to have decreased renal function it may be
useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="56d6cfb7-6194-6e99-ebc1-0e2470a5f697"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10  OVERDOSAGE</title>
               <text>
                  <paragraph ID="p6148122">Clinical
consequences of overdosage with MultiHance have not been reported.
 Treatment of an overdosage should be directed toward support of vital
functions and prompt institution of symptomatic therapy. In a Phase
1 clinical study, doses up to 0.4 mmol/kg were administered to patients.
 MultiHance has been shown to be dialyzable [<content styleCode="italics">
                        <content styleCode="emphasis">see
Clinical Pharmacology <linkHtml href="#Section_12.3">(12.3)</linkHtml>
                        </content>
                     </content>].</paragraph>
               </text>
               <effectiveTime value="20130122"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="16bca027-b4f5-45a8-992d-5c72e6071f71"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11  DESCRIPTION</title>
               <text>
                  <paragraph ID="p6165122">MultiHance injection is supplied as a sterile,
nonpyrogenic, clear, colorless to slightly yellow aqueous solution
intended for intravenous use only. Each mL of MultiHance contains
529 mg gadobenate dimeglumine and water for injection. MultiHance
contains no preservatives.</paragraph>
                  <paragraph ID="p6168122">Gadobenate
dimeglumine is chemically designated as (4RS)-[4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)] gadolinate(2-) dihydrogen
compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2) with a molecular
weight of 1058.2 and an empirical formula of C<sub>22</sub>H<sub>28</sub>GdN<sub>3</sub>O<sub>11</sub> • 2C<sub>7</sub>H<sub>17</sub>NO<sub>5</sub>.  The structural formula is as follows:</paragraph>
                  <renderMultiMedia referencedObject="mm1"/>
                  <paragraph ID="p6407122">MultiHance has a pH of 6.5-7.5. Pertinent physicochemical parameters
are provided below:</paragraph>
                  <table ID="t6410122" border="1" cellpadding="0" cellspacing="0" width="30%">
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">Osmolality</td>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">1.970 osmol/kg
@ 37°C</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">Viscosity</td>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">5.3 mPas @ 37°C</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">Density</td>
                           <td styleCode="Lrule Toprule Rrule Botrule " align="left">1.220 g/mL @ 20°C</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p6438122">MultiHance has an osmolality 6.9
times that of plasma (285 mOsmol/kg water) and is hypertonic under
conditions of use.</paragraph>
               </text>
               <effectiveTime value="20180403"/>
               <component>
                  <observationMedia ID="mm1">
                     <text>MultiHance Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="multihance-struc.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="87a3af6e-4fd2-4398-95b7-3cfd3a1d99ae"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240123"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="ef9824cb-787a-411b-b420-c053b55ea231"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph ID="p6657122">Gadobenate dimeglumine is a paramagnetic agent and, as such, develops
a magnetic moment when placed in a magnetic field. The large magnetic
moment produced by the paramagnetic agent results in a large local
magnetic field, which can enhance the relaxation rates of water protons
in its vicinity leading to an increase of signal intensity (brightness)
of tissue.</paragraph>
                        <paragraph ID="p6660122">In magnetic resonance
imaging (MRI), visualization of normal and pathological tissue depends
in part on variations in the radiofrequency signal intensity that
occur with 1) differences in proton density; 2) differences of the
spin-lattice or longitudinal relaxation times (T1); and 3) differences
in the spin-spin or transverse relaxation time (T2). When placed in
a magnetic field, gadobenate dimeglumine decreases the T1 and T2 relaxation
time in target tissues. At recommended doses, the effect is observed
with greatest sensitivity in the T1-weighted sequences.</paragraph>
                     </text>
                     <effectiveTime value="20130122"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="8f4ec7cd-9d7a-4e7c-ae62-2c4803c6feba"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2  Pharmacodynamics</title>
                     <text>
                        <paragraph ID="p6668122">Unlike other tested paramagnetic contrast agents (See Table 3), MultiHance
demonstrates weak and transient interactions with serum proteins that
causes slowing in the molecular tumbling dynamics, resulting in strong
increases in relaxivity in solutions containing serum proteins. The
improved relaxation effect can contribute to increased contrast-to-noise
ratio and lesion-to-brain ratio, which may improve visualization.</paragraph>
                        <table ID="t6671122" border="0" cellpadding="0" cellspacing="0" width="75%">
                           <caption>TABLE 3:  RELAXIVITY (mM<sup>–1</sup>s<sup>–1</sup>) OF GADOLINIUM CHELATES</caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td styleCode="Lrule Rrule " colspan="3">r<sub>1</sub> and
r<sub>2</sub> relaxivities indicate the efficiency in
shortening T1 and T2 relaxation times, respectively.<br/>
                                    <sup>1</sup> In heparinized human plasma, at 39°C.<br/>
                                    <sup>2</sup> In citrated human plasma, at 37°C.<br/>--
Not available</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule " rowspan="2">   </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="2" align="center">Human
plasma</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Botrule " align="center">r<sub>1</sub>
                                 </td>
                                 <td styleCode="Toprule Rrule Botrule " align="center">r<sub>2</sub>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule " align="left">Gadobenate</td>
                                 <td styleCode="Lrule " align="center">9.7<sup>1</sup>
                                 </td>
                                 <td styleCode="Rrule " align="center">12.5<sup>1</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule " align="left">Gadopentetate</td>
                                 <td styleCode="Lrule " align="center">4.9<sup>1</sup>
                                 </td>
                                 <td styleCode="Rrule " align="center">6.3<sup>1</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule " align="left">Gadodiamide</td>
                                 <td styleCode="Lrule " align="center">5.4<sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule " align="center">--</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Botrule " align="left">Gadoteridol</td>
                                 <td styleCode="Lrule " align="center">5.4<sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule Botrule " align="center">--</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p7432122">Disruption of the blood-brain barrier
or abnormal vascularity allows enhancement by MultiHance of lesions
such as neoplasms, abscesses, and infarcts. Uptake of MultiHance into
hepatocytes has been demonstrated.</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="2db2257d-7ffc-3632-ecc6-f5c283b8298f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics</title>
                     <text>
                        <paragraph ID="p7440122">Three single-dose intravenous studies were conducted in 32 healthy
male subjects to assess the pharmacokinetics of gadobenate dimeglumine.
The doses administered in these studies ranged from 0.005 to 0.4 mmol/kg.
Upon injection, the meglumine salt is completely dissociated from
the gadobenate dimeglumine complex. Thus, the pharmacokinetics is
based on the assay of gadobenate ion, the MRI contrast effective ion
in gadobenate dimeglumine. Data for plasma concentration and area
under the curve demonstrated linear dependence on the administered
dose. The pharmacokinetics of gadobenate ion following intravenous
administration can be best described using a two-compartment model.</paragraph>
                        <paragraph ID="p7443122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">Distribution</content>
                           </content>
                           <br/>Gadobenate ion has a rapid distribution half-life (reported
as mean ± SD) of 0.084 ± 0.012 to 0.605 ± 0.072 hours. Volume of distribution
of the central compartment ranged from 0.074 ± 0.017 to 0.158 ± 0.038
L/kg, and estimates of volume of distribution by area ranged from
0.170 ± 0.016 to 0.282 ± 0.079 L/kg. These latter estimates are approximately
equivalent to the average volume of extracellular body water in man. <content styleCode="italics">In vitro</content> studies showed no appreciable binding of gadobenate
ion to human serum proteins. Following GBCA administration, gadolinium
is present for months or years in brain, bone, skin, and other organs <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.4">(5.4)</linkHtml>]</content>.</paragraph>
                        <paragraph ID="p7452122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">Elimination</content>
                           </content>
                           <br/>Gadobenate ion is eliminated predominately via
the kidneys, with 78% to 96% of an administered dose recovered in
the urine. Total plasma clearance and renal clearance estimates of
gadobenate ion were similar, ranging from 0.093 ± 0.010 to 0.133 ±
0.270 L/hr/kg and 0.082 ± 0.007 to 0.104 ± 0.039 L/hr/kg, respectively.
The clearance is similar to that of substances that are subject to
glomerular filtration. The mean elimination half-life ranged from
1.17 ± 0.26 to 2.02 ± 0.60 hours. A small percentage of the administered
dose (0.6% to 4%) is eliminated via the biliary route and recovered
in feces.</paragraph>
                        <paragraph ID="p7461122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">Metabolism</content>
                           </content>
                           <br/>There was no detectable biotransformation of gadobenate
ion. Dissociation of gadobenate ion <content styleCode="italics">in vivo</content> has been
shown to be minimal, with less than 1% of the free chelating agent
being recovered alone in feces.</paragraph>
                        <paragraph ID="p7470122">
                           <content styleCode="bold">
                              <content styleCode="emphasis">Pharmacokinetics in Special Populations</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p7683122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">Renal Impairment: </content>
                              </content>
                           </content>A single intravenous
dose of 0.2 mmol/kg of MultiHance was administered to 20 subjects
with impaired renal function (6 men and 3 women with moderate renal
impairment [urine creatinine clearance &gt;30 to &lt;60 mL/min] and 5
men and 6 women with severe renal impairment [urine creatinine clearance
&gt;10 to &lt;30 mL/min]). Mean estimates of the elimination half-life
were 6.1 ± 3.0 and 9.5 ± 3.1 hours for the moderate and severe renal
impairment groups, respectively as compared with 1.0 to 2.0 hours
in healthy volunteers.</paragraph>
                        <paragraph ID="p7693122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">Hemodialysis: </content>
                              </content>
                           </content>A single intravenous
dose of 0.2 mmol/kg of MultiHance was administered to 11 subjects
(5 males and 6 females) with end-stage renal disease requiring hemodialysis
to determine the pharmacokinetics and dialyzability of gadobenate.
Approximately 72% of the dose was recovered by hemodialysis over a
4-hour period. The mean elimination half-life on dialysis was 1.21
± 0.29 hours as compared with 42.4 ± 24.4 hours when off dialysis.</paragraph>
                        <paragraph ID="p7703122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">Hepatic Impairment: </content>
                              </content>
                           </content>A single intravenous dose of 0.1 mmol/kg of MultiHance
was administered to 11 subjects (8 males and 3 females) with impaired
liver function (Class B or C modified Child-Pugh Classification).
Hepatic impairment had little effect on the pharmacokinetics of MultiHance
with the parameters being similar to those calculated for healthy
subjects.</paragraph>
                        <paragraph ID="p7713122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">Gender, Age, Race: </content>
                              </content>
                           </content>A multiple regression
analysis performed using pooled data from several pharmacokinetic
studies found no significant effect of sex upon the pharmacokinetics
of gadobenate. Clearance appeared to decrease slightly with increasing
age. Since variations due to age appeared marginal, dosage adjustment
for geriatric population is not recommended. Pharmacokinetic differences
due to race have not been systematically studied.</paragraph>
                        <paragraph ID="p7723122">
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <content styleCode="emphasis">Pediatric: </content>
                              </content>
                           </content>A population pharmacokinetic analysis incorporated data from
25 healthy subjects (14 males and 11 females) and 15 subjects undergoing
MR imaging of the central nervous system (7 males and 8 females) between
ages of 2 and 16 years. The subjects received a single intravenous
dose of 0.1 mmol/kg of MultiHance. The geometric mean C<sub>max</sub> was 62.3 μg/mL (n=16) in children 2 to 5 years of
age, and 64.2 μg/mL (n=24) in children older than 5 years. The geometric
mean AUC <sub>0-∞</sub> was 77.9 μg⋅h/mL in children 2-5
years of age (n=16) and 82.6 μg⋅h/mL in children older than 5 years
(n=24). The geometric mean half-life was 1.2 hours in children 2 to
5 years of age and 0.93 hours in children older than 5 years. There
was no significant gender-related difference in the pharmacokinetic
parameters in the pediatric patients. Over 80% of the dose was recovered
in urine after 24 hours. Pharmacokinetic simulations indicate similar
AUC and C<sub>max</sub> values for MultiHance in pediatric
subjects less than 2 years when compared to those reported for adults;
no age-based dose adjustment is necessary for this pediatric population.</paragraph>
                     </text>
                     <effectiveTime value="20240123"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="b0b80c02-182e-c3b0-b690-c1b046326102"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13  NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20180403"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="47780d0a-9b33-004d-c403-52187e04baf3"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="p7957122">Long-term animal studies have not been performed
to evaluate the carcinogenic potential of MultiHance.</paragraph>
                        <paragraph ID="p7960122">The results for MultiHance were negative in the following
genetic toxicity studies: 1)<content styleCode="italics"> in vitro</content> bacteria reverse
mutation assays, 2) an <content styleCode="italics">in vitro</content> gene mutation assay
in mammalian cells, 3) an <content styleCode="italics">in vitro</content> chromosomal aberration
assay, 4) an <content styleCode="italics">in vitro</content> unscheduled DNA synthesis assay,
and 5) an <content styleCode="italics">in vivo </content>micronucleus assay in rats.</paragraph>
                        <paragraph ID="p7963122">MultiHance had no effect on fertility and
reproductive performance at IV doses of up to 2 mmol/kg/day (3 times
the human dose on body surface basis) for 13 weeks in male rats and
for 32 days in female rats. However, vacuolation in testes and abnormal
spermatogenic cells were observed when MultiHance was intravenously
administered to male rats at 3 mmol/kg/day (5 times the human dose
on body surface basis) for 28 days. The effects were not reversible
following 28-day recovery period. The effects were not reported in
dog and monkey studies (at doses up to about 11 and 10 times the human
dose on body surface basis for dogs (28 days dosing) and monkeys (14
days dosing), respectively).</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="d412bed1-960e-4b92-b41e-ce7bf0654677"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14  CLINICAL STUDIES</title>
               <effectiveTime value="20180403"/>
               <component>
                  <section ID="Section_14.1">
                     <id root="638c583d-789e-44e9-b50c-52e43fb3b668"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.1  MRI of the CNS</title>
                     <text>
                        <paragraph ID="p7976122">Adults:<br/>MultiHance was evaluated in 426 adult patients
in 2 controlled clinical trials of the central nervous system (Study
A and Study B), enrolling 217 men and 209 women with a mean age of
52 years (range 18 to 88 years). The racial and ethnic representations
were 88% Caucasian, 6% Black, 4% Hispanic, 1% Asian, and 1% other
racial or ethnic groups. These trials were designed to compare MultiHance
contrast MRI to non-contrast MRI alone. In Study A,  patients highly
suspected of having a lesion(s) of the CNS based on nuclear medicine
imaging, computed tomography (CT), contrast CT, MRI, contrast- MRI,
or angiography were randomized to receive two MRI evaluations with
0.05 mmol/kg (n=140) or 0.1 mmol/kg (n=136) of MultiHance. In Study
B, patients with known metastatic disease to the CNS were randomized
to receive two MRI evaluations with 0.05 mmol/kg (n=74) or 0.1 mmol/kg
(n=76) of MultiHance. MRI scans were performed pre-contrast and within
5 minutes after each injection. The studies were designed to evaluate
the effect of MultiHance MRI compared to the non-contrast MRI on a
lesion level. Pre-contrast, post-contrast, and pre-plus-post contrast
images (paired images) were independently evaluated by three blinded
readers. The images were evaluated for the following endpoints using
a scale from 0 to 4: the degree of lesion border delineation, the
degree of visualization of lesion internal morphology, and the degree
of lesion contrast enhancement. Lesion counting was also performed
for the pre-contrast and paired image sets.</paragraph>
                        <paragraph ID="p7979122">The 0.1 mmol/kg dose of MultiHance demonstrated consistently
better visualization for all readers for all visualization endpoints.
However, the 0.05 mmol/kg dose of MultiHance provided inconsistent
visualization results between readers.</paragraph>
                        <paragraph ID="p7982122">Comparison of pre-contrast versus post-contrast (0.1
mmol/kg) images showed that the mean score differences were significant
and favored contrast for subjects in Study B (all subjects with known
metastatic lesions) and for subjects with known tumors in Study A.
However, the mean score differences between the pre-contrast and post-contrast
images were not significant for non-tumor patients in Study A. These
negative results may be attributed to a lack of lesion enhancement
in non-tumor CNS disease.</paragraph>
                        <paragraph ID="p7985122">Table
4 shows a comparison of paired images (pre-and post-contrast) versus
pre-contrast images with respect to the difference in the mean score
and with respect to the proportion of lesions read as better, worse,
or the same as the pre-contrast MRI images.  Table 4 shows that based
on a lesion-level analysis 0.1 mmol/kg MultiHance provided a statistically
significant improvement for the three structural parameters evaluated.
Also, more lesions were seen in the paired images than in the pre-contrast
images alone.</paragraph>
                        <table ID="t8194122" border="1" cellpadding="0" cellspacing="0" width="100%">
                           <tfoot>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="7" align="left">(a)
Difference of means = (paired mean) - (pre mean)<br/>(b) Worse
= paired score is less than the pre score<br/>Same = paired
score is the same as the pre score<br/>Better = paired score
is greater than the pre score<br/>
                                    <sup>*</sup> Statistically significant for the mean (paired t test)</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="7" align="center">
                                    <content styleCode="bold">Table 4: LESION LEVEL RESULTS OF MRI CENTRAL NERVOUS SYSTEM ADULT
STUDIES WITH 0.1 mmol/kg MULTIHANCE</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3" align="left">Study
A</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3" align="left">Study
B</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 1</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 2</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 3</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 1</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 2</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Reader 3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Endpoints</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 395</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 384</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 299</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 245</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 275</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">N = 254</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule ">Border Delineation:            </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule ">Difference of Means (a)</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.8*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.6*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.8*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.8*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.5*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.9*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Worse (b)<br/>Same<br/>Better</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">44 (11%)<br/>146 (37%)<br/>205 (52%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">61 (16%)<br/>168 (44%)<br/>155 (40%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">57 (19%)<br/>89 (30%)<br/>153 (51%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">13 (5%)<br/>11 (5%)<br/>221 (90%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">24 (9%)<br/>19 (7%)<br/>232 (84%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">15 (6%)<br/>18 (7%)<br/>221 (87%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule ">Internal Morphology:</td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule ">Difference of Means</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.8*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.6*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.7*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.7*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.4*</td>
                                 <td styleCode="Lrule Rrule Botrule ">2.1*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Worse<br/>Same<br/>Better</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">37 (10%)<br/>147 (37%)<br/>211 (53%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">63 (17%)<br/>151 (39%)<br/>170 (44%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">62 (21%)<br/>84 (28%)<br/>153 (51%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">13 (5%)<br/>16 (7%)<br/>216 (88%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">26 (10%)<br/>22 (8%)<br/>227 (82%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">14 (5%)<br/>22 (9%)<br/>218 (86%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule ">Contrast Enhancement:</td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                                 <td styleCode="Lrule Toprule Rrule "> </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Botrule ">Difference of Means</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.7*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.5*</td>
                                 <td styleCode="Lrule Rrule Botrule ">0.8*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.9*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.3*</td>
                                 <td styleCode="Lrule Rrule Botrule ">1.9*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Worse<br/>Same<br/>Better</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">75 (19%)<br/>148 (37%)<br/>172 (44%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">74 (19%)<br/>152 (40%)<br/>158 (41%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">50 (17%)<br/>109 (36%)<br/>140 (47%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">13 (5%)<br/>11 (5%)<br/>221 (90%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">32 (12%)<br/>21 (7%)<br/>222 (81%)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">17 (7%)<br/>14 (5%)<br/>223 (88%)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p10016122">Pediatric 2 to 17 years<br/>The efficacy and safety of MultiHance were evaluated in 92 pediatric
patients with known or highly suspected disease of the central nervous
system.  MRI scans were performed pre-contrast and within 3 to 10
minutes following the administration of MultiHance 0.1 mmol/kg.  Pre-contrast,
post-contrast, and pre-plus-post contrast images (paired images) were
independently evaluated by three blinded readers on a lesion level.
 The images were evaluated for the same endpoints as in the adult
central nervous system trials using a scale from 0 to 4: the degree
of lesion border delineation, the degree of visualization of lesion
internal morphology, and the degree of lesion contrast enhancement.
 Lesion counting was also performed for the pre-contrast and paired
image sets.  The pre-contrast versus the paired image set was the
primary comparison. Forty-nine percent of study subjects were male
and the overall mean age was 10.6 years (range 2 to 17 years).  The
racial and ethnic representations were 77% Caucasian, 13% Asian, 5%
Black, and 4% other racial or ethnic groups. MultiHance increased
lesion border delineation, lesion internal morphology, and lesion
contrast enhancement relative to non-contrast and these results were
comparable to those seen in adults.</paragraph>
                        <paragraph ID="p2000025141517000158">Pediatrics below 2 years<br/>A study
of 90 pediatric patients younger than 2 years of age was performed
which supports extrapolation of CNS efficacy findings from adults
and older pediatric patients.  Three independent, blinded readers
evaluated pre-contrast MRI image sets and paired pre-plus-post-contrast
MRI image sets using MultiHance and rated the images according to
three co-primary endpoints at a lesion level for the primary analysis.
Two of the three readers reported improvement in the paired image
sets in each of the three co-primary endpoints of lesion border delineation,
visualization of lesion internal morphology, and lesion contrast enhancement.</paragraph>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_14.2">
                     <id root="73741385-5fd0-4f01-b3d9-362fa31b5e24"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>14.2  MRA of Renal and Aorto-ilio-femoral Vessels</title>
                     <text>
                        <paragraph ID="p10024122">Safety and efficacy of MultiHance for use
in MRA were evaluated in two prospective, multi-center, open-label,
clinical trials (one for each arterial vascular territory: renal and
aorto-ilio-femoral). Out of 580 patients who received Multihance in
these two trials, 62.2% were men and 90.9% were Caucasian; the average
age was 63.4 years (range 18 to 93 years). In both trials, patients
with known or suspected arterial disease underwent MRA with and without
MultiHance as well as catheter-based digital subtraction angiography
(DSA). Assessment of diagnostic efficacy for detecting/excluding clinically
significant steno-occlusive disease (≥ 51% stenosis measured with
electronic calipers) was based on comparisons of sensitivity and specificity
between MultiHance MRA and non-contrast MRA, with DSA as a reference
standard.</paragraph>
                        <paragraph ID="p10030122">In each vascular territory,
the primary efficacy analyses were designed to demonstrate superiority
in sensitivity and non-inferiority in specificity of MultiHance MRA
to non-contrast MRA at the vessel-segment level. The interpretation
of MRA images from both trials was conducted by three independent
radiologist readers who were blinded to clinical data, including the
DSA results. The pre-specified success criteria were to be achieved
by at least the same two readers for all primary analyses.</paragraph>
                        <paragraph ID="p10242122">Results of both trials showed a statistically
significant increase in sensitivity and specificity of MultiHance
MRA over non-contrast MRA in detecting clinically significant steno-occlusive
disease.</paragraph>
                        <paragraph ID="p17169143371525270109">Table 5
summarizes the efficacy results by reader.</paragraph>
                        <table ID="table_5" border="1" cellpadding="1" cellspacing="1" width="100%">
                           <colgroup>
                              <col align="left" width="12*"/>
                              <col align="center" width="12*"/>
                              <col align="center" width="14*"/>
                              <col align="center" width="14*"/>
                              <col align="center" width="13*"/>
                              <col align="center" width="13*"/>
                              <col align="center" width="13*"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="7" align="center" valign="top">
                                    <content styleCode="bold">
                                       <content styleCode="emphasis">TABLE 5. PERFORMANCE CHARACTERISTICS
OF MULTIHANCE-MRA AND NON-CONTRAST MRA</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="7" align="left">* (Based
on General Delta Method)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " rowspan="3" align="center">
                                    <content styleCode="bold">READER </content>
                                 </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="6" align="center">AORTO-ILIO-FEMORAL
ARTERIES</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3">SENSITIVITY</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3">SPECIFICITY</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">MultiHance<br/>MRA [A] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Non-contrast <br/>MRA
[B] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">[A] – [B]<br/>(95% CI)*</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">MultiHance<br/>MRA [A] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Non-contrast <br/>MRA
[B] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">[A] – [B]<br/>(95% CI)*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">1</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">77.8%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">73.7%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">4.5<br/>(1.5, 7.6)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">88.1%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">78.5%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">10.0 <br/>(7.3, 12.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">2</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">65.2% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">52.5% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">12.6 <br/>(8.5, 16.6)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">94.2% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">89.4% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">4.9<br/>(2.7, 7.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">3</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">69.0% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">59.1% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">10.0 <br/>(6.1, 14.0)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">90.0% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">75.3% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">14.9<br/>(12.1, 17.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " rowspan="3" align="center"> <content styleCode="bold">READER </content>
                                 </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="6">RENAL ARTERIES</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3" align="center">SENSITIVITY</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " colspan="3">SPECIFICITY</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">MultiHance<br/>MRA [A] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Non-contrast <br/>MRA
[B] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">[A] – [B]<br/>(95% CI)*</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">MultiHance<br/>MRA [A] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">Non-contrast <br/>MRA
[B] </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">[A] – [B]<br/>(95% CI)*</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">1</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">67.8%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">47.0%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">20.8<br/>(12.8, 28.9)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">94.0% </td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">86.1%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">8.3<br/>(4.2,  12.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">2</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">62.4%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">46.7%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">16.2<br/>(6.8, 25.6)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule "> 94.0%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">83.5%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">10.3<br/>(5.5, 15.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Toprule Rrule Botrule " align="center">3</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">65.5%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">39.6%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="top">25.3<br/>(15.9,  34.6)</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">94.7%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule ">87.3%</td>
                                 <td styleCode="Lrule Toprule Rrule Botrule " valign="bottom">8.0<br/>(3.6, 12.5)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="c58265cb-ce91-acaa-4657-e695a744cecb"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16  HOW SUPPLIED/STORAGE
AND HANDLING</title>
               <text>
                  <paragraph ID="p1743848711525286805">
                     <content styleCode="bold">16.1  How Supplied</content>
                     <br/>MultiHance (gadobenate
dimeglumine) is a clear, colorless to slightly yellow solution containing
529 mg gadobenate dimeglumine per mL. MultiHance is supplied in glass
vials; each single dose vial is rubber stoppered with an aluminum
seal and the contents are sterile. MultiHance is supplied in boxes
of:</paragraph>
                  <paragraph ID="p13864122">Five 5 mL single dose 10
mL vials              (NDC 0270-5164-12)<br/>Five 10 mL single
dose 20 mL vials           (NDC 0270-5164-13)<br/>Five 15 mL
single dose 20 mL vials           (NDC 0270-5164-14)<br/>Five
20 mL single dose 20 mL vials           (NDC 0270-5164-15)</paragraph>
                  <paragraph ID="p1745268711525286831">
                     <content styleCode="bold">16.2  Storage and Handling</content>
                     <br/>Store at 25°C (77°F), excursions permitted to 15-30°C
(59-86°F) [see USP Controlled Room Temperature]. Do not freeze.</paragraph>
               </text>
               <effectiveTime value="20180403"/>
               <component>
                  <section ID="Section_16.2">
                     <id root="0f3ac193-48ec-8ec6-d3fd-ae113162a10d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <effectiveTime value="20180403"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="cf163155-3a11-5d3b-4dff-af50d937c2d5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" ID="l1793054761522851754" styleCode="Disc">
                     <item>Advise the patient to read the FDA-approved patient labeling
(Medication Guide) found at <content styleCode="underline">www.multihancemedicationguide.com</content>.</item>
                  </list>
                  <paragraph ID="p1255755141517000523">
                     <content styleCode="bold">Nephrogenic Systemic
Fibrosis</content>
                     <br/>Instruct patients to inform their physician
if they:</paragraph>
                  <list listType="unordered" ID="l14110122" styleCode="Disc">
                     <item>have a history of kidney and/or liver disease, or</item>
                     <item>have recently received a GBCA.</item>
                  </list>
                  <paragraph ID="p14118122">GBCAs increase the risk for NSF among
patients with impaired elimination of the drugs. To counsel patients
at risk for NSF:</paragraph>
                  <list listType="unordered" ID="l14121122" styleCode="Disc">
                     <item>Describe the clinical manifestations of NSF</item>
                     <item>Describe procedures to screen for the detection of renal
impairment.</item>
                  </list>
                  <paragraph ID="p14129122">Instruct the patients to contact
their physician if they develop signs or symptoms of NSF following
MultiHance administration, such as burning, itching, swelling, scaling,
hardening and tightening of the skin; red or dark patches on the skin;
stiffness in joints with trouble moving, bending or straightening
the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle
weakness.</paragraph>
                  <paragraph ID="p17931145141517000613">
                     <content styleCode="bold">Common
Adverse Reactions</content>
                     <br/>Inform patients that they may
experience:</paragraph>
                  <list listType="unordered" ID="l14346122" styleCode="Disc">
                     <item> reactions along the venous injection site, such as mild
and transient burning or pain or feeling of warmth or coldness at
the injection site</item>
                     <item> side effects of feeling hot, nausea, and headache.</item>
                  </list>
                  <paragraph ID="p16401329011515688412">
                     <content styleCode="bold">Gadolinium Retention</content>
                     <br/>Advise patients that gadolinium is retained for months
or years in brain, bone, skin, and other organs in patients with normal
renal function. The clinical consequences of retention are unknown.
 Retention depends on multiple factors and is greater following administration
of linear GBCAs than following administration of macrocyclic GBCAs <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.4">(5.4)</linkHtml>]</content>.</paragraph>
                  <paragraph ID="p14376122">
                     <content styleCode="bold">
                        <content styleCode="emphasis">Rx only</content>
                     </content>
                     <br/>US Patent No. 4,916,246</paragraph>
                  <paragraph ID="p14385122">Manufactured for<br/>Bracco Diagnostics
Inc.<br/>Princeton, NJ 08540</paragraph>
                  <paragraph ID="p17449153371525270489">By BIPSO GmbH<br/>78224 Singen (Germany)</paragraph>
                  <paragraph ID="p1615269701706059638">March 2025<br/>CL44F-09</paragraph>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="s13068929011515689747">
               <id root="1d6b4646-1b4a-cfbc-f385-30ad5eb6ae2d"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table ID="Table_MedGuide" border="0" width="100%">
                     <colgroup>
                        <col span="2"/>
                     </colgroup>
                     <tfoot>
                        <tr>
                           <td valign="top">This Medication Guide has been approved by the U.S.
Food and Drug Administration</td>
                           <td align="right" valign="top">Revised: 03/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2" align="center">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <br/>
                              <content styleCode="bold">MULTIHANCE<sup>®</sup>
                                 <content styleCode="italics">(məl-tē-han(t)s)</content>
                              </content>
                              <br/>
                              <content styleCode="bold">(gadobenate dimeglumine)</content>
                              <br/>
                              <content styleCode="bold">Injection,
for intravenous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What is the
most important information I should know about MULTIHANCE?</content>
                              <list listType="unordered" ID="l16913729011515690284" styleCode="Disc">
                                 <item>GBCAs like MULTIHANCE may cause serious side effects including
death, coma, encephalopathy, and seizures when it is given intrathecally
(injection given into the spinal cord). It is not known if MULTIHANCE
is safe and effective with intrathecal use. MULTIHANCE is not approved
for this use.</item>
                                 <item>MULTIHANCE contains a metal called gadolinium. Small amounts
of gadolinium can stay in your body including the brain, bones, skin
and other parts of your body for a long time (several months to years).</item>
                                 <item>It is not known how gadolinium may affect you, but so far,
studies have not found harmful effects in patients with normal kidneys.</item>
                                 <item>Rarely, patients have reported pains, tiredness, and skin,
muscle or bone ailments for a long time, but these symptoms have not
been directly linked to gadolinium.</item>
                                 <item>There are different GBCAs that can be used for your MRI
exam.  The amount of gadolinium that stays in the body is different
for different gadolinium medicines. Gadolinium stays in the body more
after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance.
Gadolinium stays in the body the least after Dotarem, Gadavist, or
ProHance.</item>
                                 <item>People who get many doses of gadolinium medicines, women
who are pregnant and young children may be at increased risk from
gadolinium staying in the body.</item>
                                 <item>Some people with kidney problems who get gadolinium medicines
can develop a condition with severe thickening of the skin, muscles
and other organs in the body (nephrogenic systemic fibrosis). Your
healthcare provider should screen you to see how well your kidneys
are working before you receive MULTIHANCE.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What is MULTIHANCE?</content>
                              <list listType="unordered" ID="l1360652681522784944" styleCode="Disc">
                                 <item>MULTIHANCE is a prescription medicine called a gadolinium-based
contrast agent (GBCA). MULTIHANCE, like other GBCAs, is injected into
your vein and used with a magnetic resonance imaging (MRI) scanner.</item>
                                 <item>An MRI exam with a GBCA, including MULTIHANCE, helps your
doctor to see problems better than an MRI exam without a GBCA.</item>
                                 <item>Your doctor has reviewed your medical records and has determined
that you would benefit from using a GBCA with your MRI exam.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">Do not receive
MULTIHANCE if you </content>have had a severe allergic reaction to GBCAs
including gadobenate dimeglumine, or any of the ingredients in MULTIHANCE.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">Before receiving
MULTIHANCE, tell your healthcare provider about all your medical conditions,
including if you:</content>
                              <list listType="unordered" ID="l17192529011515690532" styleCode="Disc">
                                 <item>have had any MRI procedures in the past where you received
a GBCA. Your healthcare provider may ask you for more information
including the dates of these MRI procedures.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known
if MULTIHANCE can harm your unborn baby. Talk to your healthcare provider
about the possible risks to an unborn baby if a GBCA such as MULTIHANCE
is received during pregnancy</item>
                                 <item>have kidney problems, diabetes, or high blood pressure.</item>
                                 <item>have had an allergic reaction to dyes (contrast agents)
including GBCAs</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What are
the possible side effects of MULTIHANCE?</content>
                              <list listType="unordered" ID="l18225129011515690654" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">See “What is the most important information I should
know about MULTIHANCE?”</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Allergic reactions. MULTIHANCE can cause allergic
reactions that can sometimes be serious. Your healthcare provider
will monitor you closely for symptoms of an allergic reaction.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of MULTIHANCE include: nausea,
headache, feeling hot, or burning at the injection site.</content>
                              <br/>These are not all the possible side effects of MULTIHANCE.<br/>Call your doctor for medical advice about side effects. You may
report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">General information
about the safe and effective use of MULTIHANCE.</content>
                              <br/>Medicines
are sometimes prescribed for purposes other than those listed in a
Medication Guide. You can ask your healthcare provider for information
about MULTIHANCE that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule Rrule Botrule " colspan="2">
                              <content styleCode="bold">What are
the ingredients in MULTIHANCE?<br/>Active ingredient: gadobenate
dimeglumine<br/>Inactive ingredients: water</content>
                              <br/>Manufactured by: BIPSO GmbH-78224 Singen (Germany)<br/>Manufactured
for: Bracco Diagnostics Inc., Princeton, NJ 08540<br/>US Patent
No. 4,916,246<br/>For more information, go to www.imaging.bracco.com
or call 1-800-257-5181.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250314"/>
            </section>
         </component>
         <component>
            <section ID="g929dd675-8f69-b33a-c77f-5bb6af6b1e92">
               <id root="30175440-c5bd-d34a-ded1-4c90e2ee558c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p12322">MultiHance<sup>®</sup> Injection 15 mL<br/>NDC 0270–5164–14</paragraph>
                  <renderMultiMedia referencedObject="g225301732571995"/>
                  <br/>
                  <renderMultiMedia referencedObject="g143301732629968"/>
               </text>
               <effectiveTime value="20241126"/>
               <component>
                  <observationMedia ID="g225301732571995">
                     <text>multihance-box-15-ml</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="multihance-box-15-ml.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="g143301732629968">
                     <text>multihance-15-ml-vial-label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="multihance-15-ml-vial-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>